[go: up one dir, main page]

MX2012002630A - Regimen de inmunizacion por sensibilizacion-refuerzo heterologa contra el virus de la lengua azul. - Google Patents

Regimen de inmunizacion por sensibilizacion-refuerzo heterologa contra el virus de la lengua azul.

Info

Publication number
MX2012002630A
MX2012002630A MX2012002630A MX2012002630A MX2012002630A MX 2012002630 A MX2012002630 A MX 2012002630A MX 2012002630 A MX2012002630 A MX 2012002630A MX 2012002630 A MX2012002630 A MX 2012002630A MX 2012002630 A MX2012002630 A MX 2012002630A
Authority
MX
Mexico
Prior art keywords
virus
heterology
sensitization
reinforcement
language
Prior art date
Application number
MX2012002630A
Other languages
English (en)
Inventor
David Jaimes Bartram
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42829427&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012002630(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MX2012002630A publication Critical patent/MX2012002630A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona procedimientos para inducir una respuesta inmune específica de antígeno en un sujeto mediante el uso de una combinación de composiciones inmunogénicas; generalmente, el procedimiento implica la administración al sujeto de una cantidad eficaz de dos composiciones inmunogénicas diferentes, comprendiendo ambas serotipo 8 del virus de la lengua azul.
MX2012002630A 2009-09-02 2010-08-30 Regimen de inmunizacion por sensibilizacion-refuerzo heterologa contra el virus de la lengua azul. MX2012002630A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23912509P 2009-09-02 2009-09-02
PCT/US2010/047096 WO2011028652A1 (en) 2009-09-02 2010-08-30 Heterlogous prime-boost immunization regimen against bluetongue virus

Publications (1)

Publication Number Publication Date
MX2012002630A true MX2012002630A (es) 2012-05-08

Family

ID=42829427

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002630A MX2012002630A (es) 2009-09-02 2010-08-30 Regimen de inmunizacion por sensibilizacion-refuerzo heterologa contra el virus de la lengua azul.

Country Status (18)

Country Link
US (1) US20110110980A1 (es)
EP (1) EP2473190A1 (es)
JP (1) JP2013503869A (es)
KR (1) KR20120062853A (es)
CN (1) CN102481358A (es)
AR (1) AR078147A1 (es)
AU (1) AU2010289734A1 (es)
BR (1) BR112012004703A2 (es)
CA (1) CA2770070A1 (es)
CL (1) CL2012000580A1 (es)
CO (1) CO6511241A2 (es)
MX (1) MX2012002630A (es)
PH (1) PH12012500383A1 (es)
RU (1) RU2012107823A (es)
TW (1) TW201125579A (es)
UY (1) UY32876A (es)
WO (1) WO2011028652A1 (es)
ZA (1) ZA201200892B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103305471B (zh) * 2013-06-18 2014-11-05 中国农业科学院哈尔滨兽医研究所 抗蓝舌病病毒血清8型vp2蛋白的单克隆抗体btv8-vp2-4d9及其识别的b细胞表位多肽和应用
JP7513614B2 (ja) 2018-12-20 2024-07-09 インターベット インターナショナル ベー． フェー． プライム－ブーストワクチン接種レジメン
CN112870346A (zh) * 2021-01-21 2021-06-01 云南省畜牧兽医科学院 一种蓝舌病病毒二价灭活疫苗的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4567043A (en) * 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
BE1008978A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9622159D0 (en) * 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
DE69840962D1 (de) 1997-08-29 2009-08-20 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
US7862821B2 (en) * 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus

Also Published As

Publication number Publication date
TW201125579A (en) 2011-08-01
PH12012500383A1 (en) 2012-10-22
CN102481358A (zh) 2012-05-30
AR078147A1 (es) 2011-10-19
BR112012004703A2 (pt) 2016-04-12
WO2011028652A1 (en) 2011-03-10
RU2012107823A (ru) 2013-10-10
KR20120062853A (ko) 2012-06-14
UY32876A (es) 2011-04-29
JP2013503869A (ja) 2013-02-04
ZA201200892B (en) 2012-10-31
AU2010289734A1 (en) 2012-03-01
CL2012000580A1 (es) 2012-07-13
CA2770070A1 (en) 2011-03-10
EP2473190A1 (en) 2012-07-11
US20110110980A1 (en) 2011-05-12
CO6511241A2 (es) 2012-08-31

Similar Documents

Publication Publication Date Title
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
EA201100268A1 (ru) Вакцина
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
CR10559A (es) Vacuna de influenza
CO6382137A2 (es) Oligonucleótidos inmunoestimuladores
MX383065B (es) Mutantes de virus de influenza y usos para los mismos.
TW200722101A (en) Novel composition
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
AR101455A1 (es) Molécula portadora
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
CL2012003299A1 (es) Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
MX352478B (es) Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
MX2021006021A (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
AR061894A1 (es) Vacunas para malaria
EA201290956A1 (ru) Вакцина против вич
BR112015004515A2 (pt) composição imunogênica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal